248 related articles for article (PubMed ID: 29093000)
1. Pandora's Prescription: The Pharmaceutical Pricing
Pederson T
FASEB J; 2017 Nov; 31(11):4661-4662. PubMed ID: 29093000
[No Abstract] [Full Text] [Related]
2. Medicines pricing singled out.
Buchanan E
S Afr Med J; 2004 May; 94(5):334. PubMed ID: 15211941
[No Abstract] [Full Text] [Related]
3. Drug pricing in AFP--how much does a drug cost?
Siwek J
Am Fam Physician; 2010 Jan; 81(2):125. PubMed ID: 20082507
[No Abstract] [Full Text] [Related]
4. Market watch: pricing strategies for emerging markets.
Lineberry N; Snyder E; Gunda S
Nat Rev Drug Discov; 2011 Aug; 10(8):567. PubMed ID: 21804586
[No Abstract] [Full Text] [Related]
5. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
Werling K; Abraham S; Strelec J
J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994
[No Abstract] [Full Text] [Related]
6. Pharmacies take uniform price demands to court.
Moskowitz DB
J Am Health Policy; 1994; 4(4):24-7. PubMed ID: 10136676
[No Abstract] [Full Text] [Related]
7. Seizures of Canadian drugs rise as Congress, Customs spar.
Carreyrou J
Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16909501
[No Abstract] [Full Text] [Related]
8. Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK.
Ogbighele E
IDrugs; 2010 May; 13(5):317-20. PubMed ID: 20432188
[TBL] [Abstract][Full Text] [Related]
9. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
Werling K; Abraham S; Strelec J
Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
[No Abstract] [Full Text] [Related]
10. Philippines joins other developing countries in limiting prices of drugs.
Bland B
BMJ; 2009 Aug; 339():b3151. PubMed ID: 19651688
[No Abstract] [Full Text] [Related]
11. Policy Recommendations for Pharmacy Benefit Managers to Stem the Escalating Costs of Prescription Drugs: A Position Paper From the American College of Physicians.
Daniel H; Bornstein SS;
Ann Intern Med; 2019 Dec; 171(11):823-824. PubMed ID: 31711103
[TBL] [Abstract][Full Text] [Related]
12. Lower Prices and Greater Patient Access - Lessons from Germany's Drug-Purchasing Structure.
Robinson JC
N Engl J Med; 2020 Jun; 382(23):2177-2179. PubMed ID: 32492300
[No Abstract] [Full Text] [Related]
13. Can affordability and innovation coexist for medicines?
Colbert A; Rintoul A; Simão M; Hill S; Swaminathan S
BMJ; 2020 Jan; 368():l7058. PubMed ID: 31932276
[No Abstract] [Full Text] [Related]
14. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
Zhao M; Wu J
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
[TBL] [Abstract][Full Text] [Related]
15. Sir Michael Rawlins on being NICE--and fair--about drug development and availability. Interview by Daniel Clarke.
Rawlins SM
Drug Discov Today; 2005 Mar; 10(6):383-6. PubMed ID: 15808816
[No Abstract] [Full Text] [Related]
16. Pricing of pharmaceuticals is becoming a major challenge for health systems.
Morgan SG; Bathula HS; Moon S
BMJ; 2020 Jan; 368():l4627. PubMed ID: 31932289
[No Abstract] [Full Text] [Related]
17. Pharmaceutical Research and Manufacturers of America v. Walsh: the Supreme Court allows the states to proceed with expanding access to drugs.
Jost TS
Yale J Health Policy Law Ethics; 2004; 4(1):69-84. PubMed ID: 15052860
[No Abstract] [Full Text] [Related]
18. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
Bardey D; Bommier A; Jullien B
J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
[TBL] [Abstract][Full Text] [Related]
19. [What medication types are expended in the Argentine pharmaceutical market? A regulatory approach].
Pesce G
Medicina (B Aires); 2024; 84(2):369-371. PubMed ID: 38683528
[No Abstract] [Full Text] [Related]
20. Fake pharmaceuticals: how they and relevant legislation or lack thereof contribute to consistently high and increasing drug prices.
Moken MC
Am J Law Med; 2003; 29(4):525-42. PubMed ID: 15119247
[No Abstract] [Full Text] [Related]
[Next] [New Search]
